Continuation Breakout Analysis — 2026-11-19
Overview
Market Context: Only 1 continuation breakout signal fired today, which makes this a quiet day with no broad continuation edge. The backdrop is unfriendly: the SA regime is Cautious-Bearish, breadth is weak at 35.9% of stocks above the SMA-40, and sentiment reads Very Bearish / Bearish. Leadership is defensive, with Utilities (2.1%), Consumer Staples (1.5%) and Health Care (0.7%) on top, while Financials (-1.4%), Energy (-1.8%) and Technology (-2.5%) lag.
Quality Score: 2 / 5. A single signal with modest RVOL of 1.3 offers little breadth or sector diversity. Institutional backing is solid (250 funds), and the signal sits in a sector that is not among the weakest, but the regime caps conviction. Patience is warranted.
Sector Concentration: With one name, there is no theme trade. The only signal comes from Medical (Biotech), which loosely aligns with the relative strength in Health Care.
Top 5 Picks
Only one candidate qualified today, so this section covers a single pick.
URGN ($31.73) — Medical / Medical - Revenue Biotech
Open full analysis on WaveFinder →
Technical Setup: URGN is up 6.5% on RVOL of 1.3, which is only modestly above average participation. ATR%-M is -1.5, so momentum is not especially strong. The stock trades between zones: monthly demand at $22.675–$28.13 (strength 7, 11.35% below) and daily supply at $42.76–$44.08 (strength 6.3, 34.76% away). It is 37.5% below its 52-week high and 92.3% above its 52-week low, so it is a recovering name with a long way back to the highs. The wide gap to supply leaves room to run, but the weak regime and ADR of 8.4% argue for tight risk control. Risk (ATR) is 103.3%, which signals an elevated stop distance relative to normal volatility.
| Level | Price | Note |
|---|---|---|
| Entry | $31.73 | Current price; a pullback toward $30 is preferable |
| Stop | $28.13 | Upper edge of monthly demand zone (11.35% risk) |
| Target 1 | $42.76 | Lower edge of daily supply zone |
| Target 2 | $44.08 | Upper edge of daily supply zone |
Institutional Backing: 250 funds hold the stock, with classification in Buckets B0, B1 and B2, a broad institutional footprint.
Honorable Mentions
No additional tickers qualified today, so there are no honorable mentions.
Strategy Summary
- Overall quality: Weak. One signal, moderate RVOL, and a Cautious-Bearish regime mean there is no broad continuation edge today.
- Key sectors: Medical (Biotech) only, consistent with the relative strength in defensive Health Care.
- Risk/reward: From $31.73, a move to the $42.76 supply zone is roughly +34.8% versus about 11.35% risk to the $28.13 demand edge, a reward-to-risk near 3:1 on paper. The high ATR-based risk (103.3%) and a weak market suggest reduced position size.
- Approach: Be selective. Favor a pullback entry, respect the demand-zone stop, and avoid forcing trades on a thin signal day.
This analysis is for informational purposes only and is not investment advice.
Signals
- Price
- $31.73
- Entry
- $31.73
- Stop
- $28.13
- Target
- $42.76
- Target 2
- $44.08